
- /
- Supported exchanges
- / US
- / TRVI.NASDAQ
Trevi Therapeutics Inc (TRVI NASDAQ) stock market data APIs
Trevi Therapeutics Inc Financial Data Overview
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Trevi Therapeutics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Trevi Therapeutics Inc data using free add-ons & libraries
Get Trevi Therapeutics Inc Fundamental Data
Trevi Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -51 372 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Trevi Therapeutics Inc News

Haduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan Stanley
Trevi Therapeutics Inc. (NASDAQ:TRVI) is one of the best multibagger stocks to invest in right now. On August 21, Morgan Stanley’s Judah Frommer initiated coverage of the stock with an Overweight ra...


Trevi spikes as B. Riley reportedly cites deal prospects
[Wall street] Trevi Therapeutics (NASDAQ:TRVI [https://seekingalpha.com/symbol/TRVI]), a clinical-stage biopharma focused on treatments for cough conditions, traded higher on Wednesday after B. Riley...

CoreWeave upgraded, Instacart downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...

Trevi Therapeutics outlines $204M cash runway into 2029 as Phase III programs advance following positive CORAL data
Earnings Call Insights: Trevi Therapeutics (TRVI) Q2 2025 MANAGEMENT VIEW * Jennifer L. Good, CEO, described the first half of the year as a major inflection point for Trevi, highlighting positive...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.